[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"helicobacter-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:helicobacter-infection":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,74,102,124,158],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100652145","the-prevalence-and-the-pathophysiological-role-of-non-helicobacter-pylori-helicobacter-spp-in-well-defined-gastric-diseases-and-pre--malignancies-100652145",false,"NCT07770126","The Prevalence and the Pathophysiological Role of Non-Helicobacter Pylori Helicobacter Spp. in Well-defined Gastric Diseases and (Pre-) Malignancies","HELIS","Inclusion Criteria:\n\n* part of the study population\n\nExclusion Criteria:\n\n* Patients with a history of H. pylori infection diagnosed by serology, on gastric biopsy, by breath test or on antigen test in stool samples.\n* Pregnancy.\n* Underage patients (\\\u003C 18 years).",true,"ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","The goal of this clinical trial is to discover the prevalence of NHPH bacteria (Non-Helicobacter pylori Helicobacter species) in patients with one of the following conditions:\n\n1. Functional dyspepsia following the Rome IV criteria\n2. Active chronic gastritis, non-H. pylori induced atrophic gastritis, intestinal metaplasia and non-H.pylori gastric dysplasia\n3. Gastric cancer, including siewert type 2 and 3 esophagastric junction cancers In addition, patients undergoing bariatric surgery are included as a control group. This study will be conducted using a prospective analysis in the three targeted study populations. Biopsy specimens routinely taken during the medical procedure or via the resected material in patients belonging to the target groups will be used.\n\nExclusion criteria:\n\n* Patients with a history of H. pylori infection diagnosed by serology, on gastric biopsy, by breath test or on antigen test in stool samples.\n* Pregnancy.\n* Underage patients (\\\u003C 18 years).",[25,26,27,28,29,30,31,32,33],"Functional Dyspepsia","Gastritis","Gastritis Chronic","Gastric Cancer (GC)","Atrophic Gastritis","Intestinal Metaplasia of Gastric Mucosa","Dysplasia Stomach","Helicobacter Infection","NHPH Prevalence","RECRUITING","2026-08-12",{"date":37,"type":38},"2026-08-18","ACTUAL",{"date":40,"type":38},"2025-02-24",{"date":42,"type":21},"2028-03",{"name":44,"class":45},"Universiteit Antwerpen","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100648259","phase-4-efficacy-comparison-of-10-day-high-dose-versus-14-day-standard-dose-vonoprazan-plus-amoxicillin-in-helicobacter-pylori-eradication-a-multicenter-non-inferiority-randomized-controlled-trial-100648259","NCT07720037","Efficacy Comparison of 10-Day High-Dose Versus 14-Day Standard-Dose Vonoprazan Plus Amoxicillin in Helicobacter Pylori Eradication: A Multicenter Non-Inferiority Randomized Controlled Trial","Comparison of Eradication Efficacy Between 10-Day High-Dose Vonoprazan and 14-Day Standard-Dose Vonoprazan Combined With Amoxicillin for Helicobacter Pylori: A Multicenter, Non-Inferiority Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 18 to 70 years, no restriction on gender\n2. Current Helicobacter pylori infection (positive result of either ¹³C or ¹⁴C urea breath test)\n3. No prior history of Helicobacter pylori eradication therapy\n\nExclusion Criteria:\n\n1. Severe underlying diseases, including hepatic insufficiency, renal insufficiency, malignant tumors, etc.\n2. Active gastrointestinal bleeding\n3. History of upper gastrointestinal surgery\n4. History of allergy to study medications\n5. Use of bismuth agents or antibiotics within 4 weeks prior to enrollment; use of acid-suppressive agents within 2 weeks prior to enrollment\n6. Pregnant or breastfeeding women, and subjects who refuse to take contraceptive measures during the trial\n7. Behaviors that may increase disease risks, such as chronic alcohol abuse and drug addiction\n8. Subjects who are unable or unwilling to sign the informed consent form","70 Years",{"count":56,"type":21},232,"INTERVENTIONAL",[59],"PHASE4","This is a multicenter non-inferiority randomized controlled trial for patients infected with Helicobacter pylori. Eligible participants will be randomly split into two groups. One group will take high-dose vonoprazan combined with amoxicillin (vonoprazan 20mg tid, amoxicillin 1000mg bid) for 10 days, while the other group will receive standard-dose vonoprazan plus amoxicillin (vonoprazan 20mg bid, amoxicillin 1000mg bid) for 14 days. The main goal of this study is to compare how well the two treatment plans clear the H. pylori bacteria. We aim to check if the 10-day high-dose treatment works no worse than the 14-day standard treatment. Every participant will take a follow-up test after treatment to see if the bacteria have been eliminated.",[32,62,63],"Vonoprazan","Amoxicillin","NOT_YET_RECRUITING","2026-07-18",{"date":67,"type":38},"2026-07-22",{"date":69,"type":21},"2026-07-30",{"date":71,"type":21},"2028-05-30",{"name":73,"class":45},"Shandong University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":57,"phases":84,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100237761","the-efficacy-of-the-7-days-tailored-therapy-as-the-1st-eradication-of-h-pylori-infection-100237761","NCT02373280","The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection","A Prospective, Single-center, Open-label, Clinical Trial to Compare the 10-day Sequential Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter Pylori","Inclusion Criteria:\n\n* The patients who proved H. pylori infection following three methods\n\n  1. positive rapid urease test (CLOtest)\n  2. histologic evidence of H. pylori by modified Giemsa staining\n  3. positive Urea breath test\n* Male and female Korean Adult (Aged ≥ 18 years)\n\nExclusion Criteria:\n\n* Patients who received eradication therapy for H. pylori infection, previously\n* H. pylori eradication failure because of poor compliance\n* the administration of antibiotics or the consumption of bismuth salts within 4 weeks or the administration of a proton pump inhibitor (PPI) within 2 weeks\n* Advanced gastric cancer or other malignancy\n* Abnormal liver function or liver cirrhosis\n* Abnormal renal function or chronic kidney disease\n* Other severe concurrent diseases\n* Previous allergic reactions to the study drugs\n* Pregnant or lactating women","85 Years",{"count":83,"type":21},600,[85],"NA","To compare the eradication success rate between 10-days sequential therapy and 7-days tailored therapy based on H. pylori culture and antimicrobial susceptibility testing.",[32],[89,90,91],"Helicobacter pylori","tailored therapy","eradication","2026-04-23",{"date":94,"type":38},"2026-04-24",{"date":96,"type":4},"2014-08",{"date":98,"type":21},"2027-12",{"name":100,"class":45},"Seoul National University Bundang Hospital",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":16,"sex":17,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":101},"100584977","an-observational-study-for-gastric-cancer-in-carriers-of-high-risk-helicobacter-pylori-100584977","NCT06896370","An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori","Risk of Gastric Cancer in High-risk Carriers of Helicobacter Pylori: an Observational Cohort Study","Inclusion Criteria :\n\n1. Age ≥ 40 years, gender is not limited.\n2. Able and willing to provide informed consent and willing to undergo baseline and follow-up examinations.\n\nExclusion Criteria:\n\n1. A history of diagnosed gastric cancer or other malignant tumors of the digestive tract.\n2. Comorbid severe underlying conditions (e.g., severe cardiopulmonary insufficiency, liver or renal failure, etc.) that are likely to result in a short life expectancy or render long-term follow-up impractical.\n3. Severe mental illness or incapacity to participate in the study due to lack of civil behavior.\n4. Pregnant or breastfeeding women.\n5. Other conditions that the investigator deems inappropriate for participation in the study.","40 Years",{"count":111,"type":21},3000,"This study is intended to be a prospective observational cohort study. The incidence of gastric cancer and progression of gastric precancerous lesions will be compared between groups through prospective follow-up of a population with baseline negative gastric endoscopy, harboring high-risk Hp SNP subtypes and non-high-risk subtypes.",[114,32],"Gastric (Stomach) Cancer","2026-02-23",{"date":117,"type":38},"2026-02-25",{"date":119,"type":38},"2025-07-01",{"date":121,"type":21},"2035-12-31",{"name":123,"class":45},"Fudan University",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":57,"phases":134,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":101},"100615538","phase-2-vonoprazan-vs-proton-pump-inhibitor-with-vitamin-d-or-probiotics-based-triple-therapy-for-eradication-of-helicobacter-pylori-infection-100615538","NCT07293910","Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","Safety and Efficacy of Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","Inclusion Criteria:\n\n* Both male and female patients. • Patients ≥ 18 and \\\u003C80 years old.\n\nPatients with confirmed diagnosis of H. pylori infection using either stool antigen test, urea breath test or endoscopy.\n\nExclusion Criteria:\n\n* Pregnant or lactating patients. • Patients with inflammatory diseases. • Patients sensitive to any of the regimens' components. • Patients who had received a previous eradication therapy, recent use of antimicrobial agents, proton pump inhibitors, and H2 receptor blockers within 1 month.\n\nPatients with previous incidents of gastric or duodenal bleeding, gastric surgery or gastric malignancy.\n\n• Patients with active liver disease.\n\n• Patients with renal impairment.\n\n• Concurrent use of liver enzyme inducers, inhibitors or drugs with high plasma protein binding.","80 Years",{"count":133,"type":21},66,[135],"PHASE2","Helicobacter pylori is a Gram-negative, spiral-shaped bacterium that infects up to 50% of the world's population, residing in the gastric mucosa and using the mucus layer for protection from the stomach's high acidity. Its clinical significance is profound: it is classified as a Group 1 carcinogen by the World Health Organization and is a primary cause of chronic gastritis, peptic ulcers, gastric lymphoma, and gastric carcinoma. The current first-line treatment, a PPI-based triple therapy (PPI + clarithromycin + amoxicillin), is experiencing a decline in efficacy (cure rates of 50-70%) due to widespread antibiotic resistance and compliance issues. To overcome this, newer agents like Vonoprazan Fumarate, a Potassium-Competitive Acid Blocker (P-CAB), are being adopted. Vonoprazan works by reversibly inhibiting the H+, K+ ATPase pump achieving stronger and longer-lasting acid suppression than PPIs because it does not require acid activation and is more stable in an acidic environment. In addition to pharmacological treatment, adjunctive therapies show promise. Vitamin D, acting through Vitamin D Receptor (VDR), assists in eradication by upregulating antimicrobial proteins like beta-defensin and cathelicidin, and its metabolite can cause bacterial cell lysis. Probiotics (primarily Lactobacillus and Bifidobacterium strains) enhance eradication rates by restricting bacterial growth, inhibiting adhesion, and exerting an anti-inflammatory effect through decreased interleukin-8 production. Finally, helicobacter pylori infection is marked by significant inflammation and oxidative stress. The bacterial protein TIP alpha induces high levels of the pro-inflammatory cytokine TNF alpha. Furthermore, the infection increases free radical production, leading to oxidative stress reflected by high levels of malondialdehyde. Systemic inflammation is also evident as helicobacter pylori infection is associated with significantly elevated serum C-reactive protein levels, which decrease upon successful eradication.\n\nAim of the work:\n\nThis study aims at evaluating the safety and efficacy of Vonoprazan vs Proton Pump Inhibitor with Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection.",[138,32,139,140],"HELICOBACTER PYLORI INFECTIONS","Helicobacter Pylori Gastrointestinal Tract Infection","Helicobacter Pylori Infected Patients",[142,62,143,144,145,146,147,148],"Helicobacter Pylori","Vitamin D","Probiotics","Lactobacillus","C-reactive protein","Tumor necrosis factor alpha","Malondialdehyde","2026-02-11",{"date":151,"type":38},"2026-02-13",{"date":153,"type":21},"2026-02-15",{"date":155,"type":21},"2026-12-20",{"name":157,"class":45},"Tanta University",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":57,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":4},"100601798","phase-4-clinical-trial-to-evaluate-the-efficacy-of-probit-based-triple-therapy-for-helicobacter-pylori-eradication-100601798","NCT07115173","Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication","A Single-Center, Single-Arm Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication","Inclusion Criteria:\n\n1. Male or female, aged 19 to 75 years at consent.\n2. Confirmed H. pylori positive by urease breath or enzyme test.\n3. Require eradication therapy due to at least one condition: chronic atrophic gastritis, peptic ulcer, history of early gastric cancer or adenoma resection, functional dyspepsia, low-grade MALT lymphoma, idiopathic thrombocytopenic purpura, iron deficiency anemia, hyperplastic polyps, or family history of gastric cancer.\n4. Agree to use medically acceptable contraception during the trial (including medically sterile women such as menopausal, hysterectomy, tubal ligation, or bilateral oophorectomy).\n5. Provide voluntary written informed consent.\n\nExclusion Criteria:\n\n1. History of receiving H. pylori eradication therapy prior to study participation.\n2. Known hypersensitivity to the investigational product, penicillin-class antibiotics, or macrolide-class antibiotics.\n3. Current use of medications contraindicated with the investigational product or concomitant therapy.\n4. Abnormal laboratory values in blood chemistry tests as defined by the protocol.\n5. pregnant or nursing women","19 Years","75 Years",{"count":168,"type":21},103,[59],"This is a single-center, open-label, non-randomized, single-arm clinical study. Eligible participants who provide written informed consent will undergo screening based on inclusion\u002Fexclusion criteria. Enrolled subjects will receive the investigational treatment: Zastaprazan 20 mg (twice daily), clarithromycin 500 mg (twice daily), and amoxicillin 1000 mg (three times daily) for 14 days. Four to eight weeks after completing the therapy, participants will return for a urea breath test to assess H. pylori eradication. The study will also investigate the efficacy of this therapy in clarithromycin-resistant patients to indirectly assess the potential of a dual regimen using Zastaprazan and amoxicillin.",[32],"2025-08-11",{"date":174,"type":38},"2025-08-14",{"date":176,"type":21},"2025-12-01",{"date":178,"type":21},"2027-12-31",{"name":180,"class":45},"Samsung Medical Center"]